When introduced with a new immunosuppressant treatment, people with systemic lupus erythematosus (SLE) typically see clinical improvement of extrarenal flares within 6 months. A new study published in Lupus Science & Medicine found extrarenal flare activity responds well to a rapid response to established therapy, and clinically significant improvements can be achieved within 3 months of starting a new treatment. 

Researchers observed a group of 81 people with lupus over a 12-month period who were experiencing extrarenal flares and had a treatment change (both conventional and biologic drugs). They found that 3 months after starting a new immunosuppressant therapy, one-third of their flares were in remission, and 40% achieved low disease activity, regardless of whether a conventional or biological immunosuppressant therapy was administered. Over time, 64% of the participants achieved low disease activity and 42% reached remission by 6 months. By 12 months, 60% of the participants achieved low disease activity and 48% achieved remission. 

This study suggests that a 6-month period from the start of a new therapy could be the time to evaluate a treat-to-target approach in lupus treatment. Consult your physician before making any changes to your treatment plan. Treating lupus is a team effort where people with the disease work with their doctors to find the best treatment plan for them. Learn more about treating lupus. 

Read the study